These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 15351555)

  • 1. Current and new strategies in immunotherapy for superficial bladder cancer.
    Perabo FG; Müller SC
    Urology; 2004 Sep; 64(3):409-21. PubMed ID: 15351555
    [No Abstract]   [Full Text] [Related]  

  • 2. Immunotherapeutic alternatives in superficial bladder cancer. Interferon, interleukin-2, and keyhole-limpet hemocyanin.
    Sargent ER; Williams RD
    Urol Clin North Am; 1992 Aug; 19(3):581-9. PubMed ID: 1378983
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnosis and treatment of superficial bladder cancer: an update.
    Crawford ED
    Semin Urol Oncol; 1996 Feb; 14(1 Suppl 1):1-9. PubMed ID: 8727804
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravesical therapy for bladder cancer.
    Kamat AM; Lamm DL
    Urology; 2000 Feb; 55(2):161-8. PubMed ID: 10688071
    [No Abstract]   [Full Text] [Related]  

  • 5. Immunotherapy for superficial bladder cancer. A developmental and clinical overview.
    Morales A; Nickel JC
    Urol Clin North Am; 1992 Aug; 19(3):549-56. PubMed ID: 1378982
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravesical chemotherapy versus immunotherapy for superficial bladder cancer.
    Huben RP
    Semin Urol Oncol; 1996 Feb; 14(1 Suppl 1):17-22. PubMed ID: 8727806
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current state of immunotherapy for bladder cancer.
    Kassouf W; Kamat AM
    Expert Rev Anticancer Ther; 2004 Dec; 4(6):1037-46. PubMed ID: 15606331
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravesical therapy: does it affect the natural history of superficial bladder cancer?
    Lamm DL; Griffith JG
    Semin Urol; 1992 Feb; 10(1):39-44. PubMed ID: 1565903
    [No Abstract]   [Full Text] [Related]  

  • 9. The impact of age on the response of patients with superficial bladder cancer to intravesical immunotherapy.
    Joudi FN; Smith BJ; O'Donnell MA; Konety BR
    J Urol; 2006 May; 175(5):1634-9; discussion 1639-40. PubMed ID: 16600718
    [TBL] [Abstract][Full Text] [Related]  

  • 10. When does superficial bladder cancer resist intravesical therapy?
    Vögeli T; Ackermann R
    Semin Urol; 1990 Nov; 8(4):248-53. PubMed ID: 2284531
    [No Abstract]   [Full Text] [Related]  

  • 11. High-risk superficial bladder cancer: intravesical therapy for T1 G3 transitional cell carcinoma of the urinary bladder.
    Pham HT; Soloway MS
    Semin Urol Oncol; 1997 Aug; 15(3):147-53. PubMed ID: 9394909
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravesical RTNF therapy of superficial bladder cancer. A phase I study of recombinant tumor necrosis factor administered intravesically to patients with superficial bladder cancer.
    Grampsas SA; Kahn K; Crawford ED
    Online J Curr Clin Trials; 1994 Mar; Doc No 117():[4845 words; 36 paragraphs]. PubMed ID: 8136939
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of intravesical chemotherapy on recurrence rate of recurrent superficial transitional cell carcinoma of the bladder: results of a meta-analysis.
    Huncharek M; McGarry R; Kupelnick B
    Anticancer Res; 2001; 21(1B):765-9. PubMed ID: 11299841
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Point. Routine use of postoperative intravesical chemotherapy after TURBT-should it be done?
    Soloway MS; Arianayagam M
    Urology; 2010 Oct; 76(4):794-6. PubMed ID: 20932403
    [No Abstract]   [Full Text] [Related]  

  • 15. Intravesical interferon alfa in the treatment of superficial bladder cancer.
    Williams RD
    Semin Oncol; 1988 Oct; 15(5 Suppl 5):10-3. PubMed ID: 3057641
    [No Abstract]   [Full Text] [Related]  

  • 16. Keyhole-limpet hemocyanin immunotherapy in the bilharzial bladder: a new treatment modality? Phase II trial: superficial bladder cancer.
    Wishahi MM; Ismail IM; Ruebben H; Otto T
    J Urol; 1995 Mar; 153(3 Pt 2):926-8. PubMed ID: 7853576
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [ BCG-immunotherapy and bladder cancer].
    Rischmann P
    Prog Urol; 2008 May; 18 Suppl 5():S93. PubMed ID: 18585633
    [No Abstract]   [Full Text] [Related]  

  • 18. Intravesical chemotherapy for superficial bladder tumors category Ta/T1: who should be treated and how?
    Kurth KH
    Semin Urol Oncol; 1996 Feb; 14(1 Suppl 1):30-5. PubMed ID: 8727808
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase 1 trial of oral bropirimine in superficial bladder cancer.
    Sarosdy MF; Lamm DL; Williams RD; Moon TD; Flanigan RC; Crawford ED; Wilks NE; Earhart RH; Merritt JA
    J Urol; 1992 Jan; 147(1):31-3. PubMed ID: 1729546
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Treatment and follow-up of superficial bladder cancer].
    Raitanen M
    Duodecim; 2002; 118(9):903-9. PubMed ID: 12238168
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.